Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Dynamics of virus-specific T cell immunity in pediatric liver transplant recipients.

Arasaratnam RJ, Tzannou I, Gray T, Aguayo-Hiraldo PI, Kuvalekar M, Naik S, Gaikwad A, Liu H, Miloh T, Vera JF, Himes RW, Munoz FM, Leen AM.

Am J Transplant. 2018 Jun 13. doi: 10.1111/ajt.14967. [Epub ahead of print]

PMID:
29900673
2.

Enhancing the potency and specificity of engineered T cells for cancer treatment.

Sukumaran S, Watanabe N, Bajgain P, Raja K, Mohammed S, Fisher WE, Brenner MK, Leen AM, Vera JF.

Cancer Discov. 2018 Jun 7. pii: CD-17-1298. doi: 10.1158/2159-8290.CD-17-1298. [Epub ahead of print]

PMID:
29880586
3.

Infusion of cytotoxic T lymphocytes for the treatment of viral infections in hematopoetic stem cell transplant patients.

Baugh KA, Tzannou I, Leen AM.

Curr Opin Infect Dis. 2018 May 9. doi: 10.1097/QCO.0000000000000456. [Epub ahead of print]

PMID:
29750672
4.

CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation.

Bajgain P, Tawinwung S, D'Elia L, Sukumaran S, Watanabe N, Hoyos V, Lulla P, Brenner MK, Leen AM, Vera JF.

J Immunother Cancer. 2018 May 10;6(1):34. doi: 10.1186/s40425-018-0347-5.

5.

Asian elephant T cell responses to Elephant Endotheliotropic Herpesvirus (EEHV).

Fuery A, Leen AM, Peng R, Wong MC, Liu H, Ling PD.

J Virol. 2017 Dec 20. pii: JVI.01951-17. doi: 10.1128/JVI.01951-17. [Epub ahead of print]

6.

Immunologic Profiling of Human Metapneumovirus for the Development of Targeted Immunotherapy.

Tzannou I, Nicholas SK, Lulla P, Aguayo-Hiraldo PI, Misra A, Martinez CA, Machado AA, Orange JS, Piedra PA, Vera JF, Leen AM.

J Infect Dis. 2017 Sep 15;216(6):678-687. doi: 10.1093/infdis/jix358.

PMID:
28934427
7.

Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.

Tzannou I, Papadopoulou A, Naik S, Leung K, Martinez CA, Ramos CA, Carrum G, Sasa G, Lulla P, Watanabe A, Kuvalekar M, Gee AP, Wu MF, Liu H, Grilley BJ, Krance RA, Gottschalk S, Brenner MK, Rooney CM, Heslop HE, Leen AM, Omer B.

J Clin Oncol. 2017 Nov 1;35(31):3547-3557. doi: 10.1200/JCO.2017.73.0655. Epub 2017 Aug 7.

PMID:
28783452
8.

Characterizing the Cellular Immune Response to Parainfluenza Virus 3.

Aguayo-Hiraldo PI, Arasaratnam RJ, Tzannou I, Kuvalekar M, Lulla P, Naik S, Martinez CA, Piedra PA, Vera JF, Leen AM.

J Infect Dis. 2017 Jul 15;216(2):153-161. doi: 10.1093/infdis/jix203.

PMID:
28472480
9.

Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells.

Tanaka M, Tashiro H, Omer B, Lapteva N, Ando J, Ngo M, Mehta B, Dotti G, Kinchington PR, Leen AM, Rossig C, Rooney CM.

Clin Cancer Res. 2017 Jul 15;23(14):3499-3509. doi: 10.1158/1078-0432.CCR-16-2138. Epub 2017 Feb 9.

PMID:
28183713
10.

Fine-tuning the CAR spacer improves T-cell potency.

Watanabe N, Bajgain P, Sukumaran S, Ansari S, Heslop HE, Rooney CM, Brenner MK, Leen AM, Vera JF.

Oncoimmunology. 2016 Nov 8;5(12):e1253656. doi: 10.1080/2162402X.2016.1253656. eCollection 2016.

11.

Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.

Mohammed S, Sukumaran S, Bajgain P, Watanabe N, Heslop HE, Rooney CM, Brenner MK, Fisher WE, Leen AM, Vera JF.

Mol Ther. 2017 Jan 4;25(1):249-258. doi: 10.1016/j.ymthe.2016.10.016. Epub 2017 Jan 4.

12.

Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes.

Naik S, Nicholas SK, Martinez CA, Leen AM, Hanley PJ, Gottschalk SM, Rooney CM, Hanson IC, Krance RA, Shpall EJ, Cruz CR, Amrolia P, Lucchini G, Bunin N, Heimall J, Klein OR, Gennery AR, Slatter MA, Vickers MA, Orange JS, Heslop HE, Bollard CM, Keller MD.

J Allergy Clin Immunol. 2016 May;137(5):1498-1505.e1. doi: 10.1016/j.jaci.2015.12.1311. Epub 2016 Feb 24.

13.

Adoptive T cell therapy for the treatment of viral infections.

Arasaratnam RJ, Leen AM.

Ann Transl Med. 2015 Oct;3(18):278. doi: 10.3978/j.issn.2305-5839.2015.10.12. No abstract available.

14.

Preventing stem cell transplantation-associated viral infections using T-cell therapy.

Tzannou I, Leen AM.

Immunotherapy. 2015;7(7):793-810. doi: 10.2217/imt.15.43. Epub 2015 Aug 7. Review.

15.

Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational application.

Sun J, Huye LE, Lapteva N, Mamonkin M, Hiregange M, Ballard B, Dakhova O, Raghavan D, Durett AG, Perna SK, Omer B, Rollins LA, Leen AM, Vera JF, Dotti G, Gee AP, Brenner MK, Myers DG, Rooney CM.

J Immunother Cancer. 2015 Feb 18;3:5. doi: 10.1186/s40425-015-0049-1. eCollection 2015.

16.

Accelerating immune reconstitution after hematopoietic stem cell transplantation.

Tzannou I, Leen AM.

Clin Transl Immunology. 2014 Feb 28;3(2):e11. doi: 10.1038/cti.2014.2. eCollection 2014 Feb. Review.

17.

Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells.

Melenhorst JJ, Castillo P, Hanley PJ, Keller MD, Krance RA, Margolin J, Leen AM, Heslop HE, Barrett AJ, Rooney CM, Bollard CM.

Mol Ther. 2015 Jan;23(1):179-83. doi: 10.1038/mt.2014.192. Epub 2014 Sep 30.

18.

Gene therapy for rhesus monkeys heterozygous for LDL receptor deficiency by balloon catheter hepatic delivery of helper-dependent adenoviral vector.

Oka K, Mullins CE, Kushwaha RS, Leen AM, Chan L.

Gene Ther. 2015 Jan;22(1):87-95. doi: 10.1038/gt.2014.85. Epub 2014 Sep 18.

19.

Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT.

Papadopoulou A, Gerdemann U, Katari UL, Tzannou I, Liu H, Martinez C, Leung K, Carrum G, Gee AP, Vera JF, Krance RA, Brenner MK, Rooney CM, Heslop HE, Leen AM.

Sci Transl Med. 2014 Jun 25;6(242):242ra83. doi: 10.1126/scitranslmed.3008825.

20.

Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene.

Zhou X, Di Stasi A, Tey SK, Krance RA, Martinez C, Leung KS, Durett AG, Wu MF, Liu H, Leen AM, Savoldo B, Lin YF, Grilley BJ, Gee AP, Spencer DM, Rooney CM, Heslop HE, Brenner MK, Dotti G.

Blood. 2014 Jun 19;123(25):3895-905. doi: 10.1182/blood-2014-01-551671. Epub 2014 Apr 21.

21.

Reversal of tumor immune inhibition using a chimeric cytokine receptor.

Leen AM, Sukumaran S, Watanabe N, Mohammed S, Keirnan J, Yanagisawa R, Anurathapan U, Rendon D, Heslop HE, Rooney CM, Brenner MK, Vera JF.

Mol Ther. 2014 Jun;22(6):1211-1220. doi: 10.1038/mt.2014.47. Epub 2014 Mar 20.

22.

Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity.

Ngo MC, Ando J, Leen AM, Ennamuri S, Lapteva N, Vera JF, Min-Venditti A, Mims MP, Heslop HE, Bollard CM, Gottschalk S, Rooney CM.

J Immunother. 2014 May;37(4):193-203. doi: 10.1097/CJI.0000000000000014.

23.

Systemic inflammatory response syndrome after administration of unmodified T lymphocytes.

Papadopoulou A, Krance RA, Allen CE, Lee D, Rooney CM, Brenner MK, Leen AM, Heslop HE.

Mol Ther. 2014 Jun;22(6):1134-1138. doi: 10.1038/mt.2014.48. Epub 2014 Mar 21.

24.

Antiviral T-cell therapy.

Leen AM, Heslop HE, Brenner MK.

Immunol Rev. 2014 Mar;258(1):12-29. doi: 10.1111/imr.12138. Review.

25.

Optimizing the production of suspension cells using the G-Rex "M" series.

Bajgain P, Mucharla R, Wilson J, Welch D, Anurathapan U, Liang B, Lu X, Ripple K, Centanni JM, Hall C, Hsu D, Couture LA, Gupta S, Gee AP, Heslop HE, Leen AM, Rooney CM, Vera JF.

Mol Ther Methods Clin Dev. 2014 May 14;1:14015. doi: 10.1038/mtm.2014.15. eCollection 2014.

26.

T lymphocytes targeting native receptors.

Rooney CM, Leen AM, Vera JF, Heslop HE.

Immunol Rev. 2014 Jan;257(1):39-55. doi: 10.1111/imr.12133. Review.

27.

T-cell therapy for viral infections.

Heslop HE, Leen AM.

Hematology Am Soc Hematol Educ Program. 2013;2013:342-7. doi: 10.1182/asheducation-2013.1.342. Review.

PMID:
24319202
28.

Engineered T cells for cancer treatment.

Anurathapan U, Leen AM, Brenner MK, Vera JF.

Cytotherapy. 2014 Jun;16(6):713-33. doi: 10.1016/j.jcyt.2013.10.002. Epub 2013 Nov 13. Review.

29.

Kinetics of tumor destruction by chimeric antigen receptor-modified T cells.

Anurathapan U, Chan RC, Hindi HF, Mucharla R, Bajgain P, Hayes BC, Fisher WE, Heslop HE, Rooney CM, Brenner MK, Leen AM, Vera JF.

Mol Ther. 2014 Mar;22(3):623-633. doi: 10.1038/mt.2013.262. Epub 2013 Nov 28.

30.

Is cancer gene therapy an empty suit?

Brenner MK, Gottschalk S, Leen AM, Vera JF.

Lancet Oncol. 2013 Oct;14(11):e447-e456. doi: 10.1016/S1470-2045(13)70173-6. Review.

31.

Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy.

Weber G, Caruana I, Rouce RH, Barrett AJ, Gerdemann U, Leen AM, Rabin KR, Bollard CM.

Clin Cancer Res. 2013 Sep 15;19(18):5079-91. doi: 10.1158/1078-0432.CCR-13-0955. Epub 2013 Jul 9.

32.

Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant.

Gerdemann U, Katari UL, Papadopoulou A, Keirnan JM, Craddock JA, Liu H, Martinez CA, Kennedy-Nasser A, Leung KS, Gottschalk SM, Krance RA, Brenner MK, Rooney CM, Heslop HE, Leen AM.

Mol Ther. 2013 Nov;21(11):2113-21. doi: 10.1038/mt.2013.151. Epub 2013 Jun 20.

33.

Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.

Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH, Kapoor N, Pai SY, Rowley SD, Kebriaei P, Dey BR, Grilley BJ, Gee AP, Brenner MK, Rooney CM, Heslop HE.

Blood. 2013 Jun 27;121(26):5113-23. doi: 10.1182/blood-2013-02-486324. Epub 2013 Apr 22.

34.

Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant.

Weber G, Gerdemann U, Caruana I, Savoldo B, Hensel NF, Rabin KR, Shpall EJ, Melenhorst JJ, Leen AM, Barrett AJ, Bollard CM.

Leukemia. 2013 Jul;27(7):1538-47. doi: 10.1038/leu.2013.66. Epub 2013 Mar 1.

35.

Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.

Sanchez C, Chan R, Bajgain P, Rambally S, Palapattu G, Mims M, Rooney CM, Leen AM, Brenner MK, Vera JF.

Prostate Cancer Prostatic Dis. 2013 Jun;16(2):123-31, S1. doi: 10.1038/pcan.2012.49. Epub 2013 Jan 8.

36.

Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies.

Ramos CA, Narala N, Vyas GM, Leen AM, Gerdemann U, Sturgis EM, Anderson ML, Savoldo B, Heslop HE, Brenner MK, Rooney CM.

J Immunother. 2013 Jan;36(1):66-76. doi: 10.1097/CJI.0b013e318279652e.

37.

Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation.

Gerdemann U, Keukens L, Keirnan JM, Katari UL, Nguyen CT, de Pagter AP, Ramos CA, Kennedy-Nasser A, Gottschalk SM, Heslop HE, Brenner MK, Rooney CM, Leen AM.

Blood. 2013 Jan 3;121(1):207-18. doi: 10.1182/blood-2012-05-430413. Epub 2012 Nov 14.

38.

T-cell therapy: a powerful tool for the management of viral infections and relapse post hematopoietic stem cell transplantation.

Kaloyannidis P, Leen AM, Papadopoulou A.

Expert Rev Hematol. 2012 Oct;5(5):471-3. doi: 10.1586/ehm.12.38. No abstract available.

PMID:
23146049
39.

Enhancing immune reconstitution: from bench to bedside.

van Den Brink M, Leen AM, Baird K, Merchant M, Mackall C, Bollard CM.

Biol Blood Marrow Transplant. 2013 Jan;19(1 Suppl):S79-83. doi: 10.1016/j.bbmt.2012.09.016. Epub 2012 Oct 3. Review. No abstract available.

40.

Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections.

Gerdemann U, Keirnan JM, Katari UL, Yanagisawa R, Christin AS, Huye LE, Perna SK, Ennamuri S, Gottschalk S, Brenner MK, Heslop HE, Rooney CM, Leen AM.

Mol Ther. 2012 Aug;20(8):1622-32. doi: 10.1038/mt.2012.130. Epub 2012 Jul 17.

41.

Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients.

Pesonen S, Diaconu I, Kangasniemi L, Ranki T, Kanerva A, Pesonen SK, Gerdemann U, Leen AM, Kairemo K, Oksanen M, Haavisto E, Holm SL, Karioja-Kallio A, Kauppinen S, Partanen KP, Laasonen L, Joensuu T, Alanko T, Cerullo V, Hemminki A.

Cancer Res. 2012 Apr 1;72(7):1621-31. doi: 10.1158/0008-5472.CAN-11-3001. Epub 2012 Feb 9.

42.

Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma.

Ghazi A, Ashoori A, Hanley PJ, Brawley VS, Shaffer DR, Kew Y, Powell SZ, Grossman R, Grada Z, Scheurer ME, Hegde M, Leen AM, Bollard CM, Rooney CM, Heslop HE, Gottschalk S, Ahmed N.

J Immunother. 2012 Feb-Mar;35(2):159-68. doi: 10.1097/CJI.0b013e318247642f.

43.
44.

Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma.

Gerdemann U, Katari U, Christin AS, Cruz CR, Tripic T, Rousseau A, Gottschalk SM, Savoldo B, Vera JF, Heslop HE, Brenner MK, Bollard CM, Rooney CM, Leen AM.

Mol Ther. 2011 Dec;19(12):2258-68. doi: 10.1038/mt.2011.167. Epub 2011 Sep 13.

45.

Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4.

Cruz CR, Gerdemann U, Leen AM, Shafer JA, Ku S, Tzou B, Horton TM, Sheehan A, Copeland A, Younes A, Rooney CM, Heslop HE, Bollard CM.

Clin Cancer Res. 2011 Nov 15;17(22):7058-66. doi: 10.1158/1078-0432.CCR-11-1873. Epub 2011 Sep 9. Erratum in: Clin Cancer Res. 2012 Feb 1;18(3):913. Dosage error in article text.

46.

Engineered T cells for pancreatic cancer treatment.

Katari UL, Keirnan JM, Worth AC, Hodges SE, Leen AM, Fisher WE, Vera JF.

HPB (Oxford). 2011 Sep;13(9):643-50. doi: 10.1111/j.1477-2574.2011.00344.x. Epub 2011 Jul 20.

47.

PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor.

Nakazawa Y, Huye LE, Salsman VS, Leen AM, Ahmed N, Rollins L, Dotti G, Gottschalk SM, Wilson MH, Rooney CM.

Mol Ther. 2011 Dec;19(12):2133-43. doi: 10.1038/mt.2011.131. Epub 2011 Jul 19.

48.

Generation of multivirus-specific T cells to prevent/treat viral infections after allogeneic hematopoietic stem cell transplant.

Gerdemann U, Vera JF, Rooney CM, Leen AM.

J Vis Exp. 2011 May 27;(51). pii: 2736. doi: 10.3791/2736.

49.

Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma.

Bollard CM, Gottschalk S, Helen Huls M, Leen AM, Gee AP, Rooney CM.

Cytotherapy. 2011 May;13(5):518-22. doi: 10.3109/14653249.2011.561983. Epub 2011 Mar 1. No abstract available.

50.

Adoptive immunotherapy for herpesviruses.

Leen AM, Sili U, Bollard CM, Rooney CM.

In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K, editors. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press; 2007. Chapter 74.

Supplemental Content

Support Center